Changes in generic pill color and shape disrupt use

Generic versions of the same prescription drug are clinically interchangeable but often look different depending on the manufacturer. The FDA does not require consistent pill appearance among interchangeable generic drugs, and the shape and color of patients' pills may vary based on the particular supply at the patient's pharmacy. Studying a national cohort of patients who recently suffered a heart attack, researchers from Brigham and Women's Hospital (BWH) have found that variation in appearance of generic drugs is associated with a greater risk of patients stopping their essential post-heart attack drugs. These findings are published on July 14, 2014 in the Annals of Internal Medicine.

"After have a first heart attack, guidelines mandate treatment with an array of long-term medications and stopping these medications may ultimately increase morbidity and mortality," explains Aaron S. Kesselheim, MD, JD, MPH, assistant professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics at BWH and senior investigator of this study. "Medications are essential to the treatment of cardiovascular disease and our study found that pill appearance plays an important role in ensuring patients are taking the that they need."

In a large national insurance database, the researchers collected records of over 10,000 patients discharged between 2006 and 2011 after hospitalizations for heart attacks who initiated treatment with generic beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin-II-receptor blockers, or cholesterol-lowering statins. They then looked for breaks in medication refilling (non-adherence) and they determined whether the pill appearance had changed in the prior two prescriptions. They found that the odds that a patient would discontinue use or not refill their medication increased by 34 percent after a change in color and 66 percent after a change in pill shape.

"The association between changes in pill appearance and non-adherence to essential cardiovascular medications has important implications for public health," explained Kesselheim. "This study suggests the need for physicians and pharmacists to proactively warn patients about the potential for these changes, and reassure them that generic drugs are clinically interchangeable no matter how they look, especially in light of the prevalent use of and importance of promoting patient adherence to essential medications."

Related Stories

FDA approves generic version of celebrex

date Jun 03, 2014

(HealthDay)—The U.S. Food and Drug Administration on Friday gave its approval to the first generic version of the pain reliever Celebrex (celecoxib).

Recommended for you

Teva to lift bid for Mylan: report

date 3 hours ago

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

Vaccine for West Nile Virus enters human clinical trials

date 7 hours ago

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

FDA clears drug for leading form of cystic fibrosis

date Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.